Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research: Demand for Innovative Drug Clinical Trials Shifting to CN; TIGERMED (03347.HK) TP Lifted to $41.8
Recommend 13 Positive 14 Negative 9 |
||||
|
||||
|
The acceleration of new drug clinical trials, driven by policy support, is significantly beneficial for CROs, HSBC Global Research issued a research report saying. The demand for innovative drug clinical trials is shifting towards China, and the China clinical trial industry is demonstrating higher efficiency and efficacy. Therefore, the broker was optimistic about TIGERMED (03347.HK), with rating at Buy on TIGERMED's H-shares, and lifted its target price from $39.5 to $41.8. China is catching up with the world by enhancing its competitiveness, according to the report. In June, the National Medical Products Administration (NMPA) announced a proposal to reduce the review and approval time for all innovative drug clinical trial applications from 60 days to 30 days. China's clinical trial environment has significantly improved, with the CAGR of new drug clinical trial applications of Chinese pharmas reaching approx. 18.8% over the past decade, reflecting higher efficiency in the Chinese clinical trial market, HSBC Global Research noted. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
